<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32169920</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J Nucl Med</ISOAbbreviation></Journal><ArticleTitle>Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands.</ArticleTitle><Pagination><StartPage>1621</StartPage><EndPage>1627</EndPage><MedlinePgn>1621-1627</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2967/jnumed.119.241059</ELocationID><Abstract><AbstractText>Neuroinflammation has been implicated in amyotrophic lateral sclerosis (ALS) and can be visualized using translocator protein (TSPO) radioligands. To become a reliable pharmacodynamic biomarker for ALS multicenter trials, TSPO radioligands have some challenges to overcome. We aimed to investigate whether multicenter data pooling of different TSPO tracers (<sup>11</sup>C-PBR28 and <sup>18</sup>F-DPA714) is feasible, after validation of an established <sup>11</sup>C-PBR28 PET pseudo reference analysis technique for <sup>18</sup>F-DPA714. <b>Methods:</b> Seven ALS patients from Belgium (58.9 &#xb1; 6.7 y old, 5 men and 2 women), 8 healthy volunteers from Belgium (52.1 &#xb1; 15.2 y old, 3 men and 5 women), 7 ALS patients from the United States (53.4 &#xb1; 9.8 y old, 5 men and 2 women), and 7 healthy volunteers from the United States (54.6 &#xb1; 9.6 y old, 4 men and 3 women) from a previously published study underwent dynamic <sup>18</sup>F-DPA714 (Leuven, Belgium) or <sup>11</sup>C-PBR28 (Boston, Massachusetts) PET/MRI. For <sup>18</sup>F-DPA714, maps of total volume of distribution (V<sub>T</sub>) were compared with SUV ratio (SUVR) images from 40 to 60 min after injection (SUVR<sub>40-60</sub>) calculated using the pseudo reference regions cerebellum, occipital cortex, and whole brain (WB) without ventricles. For <sup>11</sup>C-PBR28, SUVR images from 60 to 90 min after injection using the WB without ventricles were calculated. <b>Results:</b> In line with previous studies, increased <sup>18</sup>F-DPA714 uptake (17.0% &#xb1; 5.6%) in primary motor cortices was observed in ALS subjects, as measured by both V<sub>T</sub> and SUVR<sub>40-60</sub> approaches. The highest sensitivity was found for SUVR calculated using the WB without ventricles (average cluster, 21.6% &#xb1; 0.1%). <sup>18</sup>F-DPA714 V<sub>T</sub> ratio was highly correlated with the SUVR<sub>40-60</sub> (<i>r</i> &gt; 0.8, <i>P</i> &lt; 0.001). A similar pattern of increased uptake (average cluster, 20.5% &#xb1; 0.5%) in the primary motor cortices was observed in ALS subjects for <sup>11</sup>C-PBR28 SUVR calculated using the WB without ventricles. Analysis of the <sup>18</sup>F-DPA714 and <sup>11</sup>C-PBR28 data together resulted in a more extensive pattern of significantly increased glial activation bilaterally in the primary motor cortices. <b>Conclusion:</b> The same pseudo reference region analysis technique for <sup>11</sup>C-PBR28 PET can be extended toward <sup>18</sup>F-DPA714 PET. Therefore, in ALS, standardized analysis across these 2 tracers enables pooling of TSPO PET data across multiple centers and increases the power of TSPO as a biomarker for future therapeutic trials.</AbstractText><CopyrightInformation>&#xa9; 2020 by the Society of Nuclear Medicine and Molecular Imaging.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Weehaeghe</LastName><ForeName>Donatienne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Subdivision, Department of Imaging and Pathology, University Hospital Leuven, Leuven, Belgium donatienne.vanweehaeghe@uzleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babu</LastName><ForeName>Suma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vocht</LastName><ForeName>Joke</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Leuven, and Laboratory of Neurobiology, Center for Brain and Disease Research, VIB, Leuven, Belgium; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Z&#xfc;rcher</LastName><ForeName>Nicole R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Sheena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chieh-En J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loggia</LastName><ForeName>Marco L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koole</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Subdivision, Department of Imaging and Pathology, University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezaei</LastName><ForeName>Ahmadreza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Subdivision, Department of Imaging and Pathology, University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schramm</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Subdivision, Department of Imaging and Pathology, University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Leuven, and Laboratory of Neurobiology, Center for Brain and Disease Research, VIB, Leuven, Belgium; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooker</LastName><ForeName>Jacob M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Laere</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Subdivision, Department of Imaging and Pathology, University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atassi</LastName><ForeName>Nazem</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S10 OD023517</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS083715</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081">Acetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C530129">N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo(1,5-a)pyrimidin-3-yl)acetamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C526798">N-(2-methoxybenzyl)-N-(4-phenoxypyridin-3-yl)acetamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018079">Receptors, GABA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C499229">TSPO protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018079" MajorTopicYN="N">Receptors, GABA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">11C-PBR28</Keyword><Keyword MajorTopicYN="N">18F-DPA714</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">multicenter</Keyword><Keyword MajorTopicYN="N">translocator protein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32169920</ArticleId><ArticleId IdType="pmc">PMC9364895</ArticleId><ArticleId IdType="doi">10.2967/jnumed.119.241059</ArticleId><ArticleId IdType="pii">jnumed.119.241059</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. . Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085.</Citation><ArticleIdList><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Werry EL, Bright FM, Piguet O, et al. . Recent developments in TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders. Int J Mol Sci. 2019;20:3161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6650818</ArticleId><ArticleId IdType="pubmed">31261683</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DR, Yeo AJ, Gunn RN, et al. . An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323305</ArticleId><ArticleId IdType="pubmed">22008728</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam MM, Lee J, Lee SY. Recent progress in the development of TSPO PET ligands for neuroinflammation imaging in neurological diseases. Nucl Med Mol Imaging. 2017;51:283&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5721086</ArticleId><ArticleId IdType="pubmed">29242722</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;rcher NR, Loggia ML, Lawson R, et al. . Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [11C]-PBR28. Neuroimage Clin. 2015;7:409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho MJ, Zurcher NR, Loggia ML, et al. . Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology. 2016;87:2554&#x2013;2561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5207001</ArticleId><ArticleId IdType="pubmed">27837005</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho MJ, Zurcher NR, Loggia ML, et al. . Integrated magnetic resonance imaging and [11C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann Neurol. 2018;83:1186&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105567</ArticleId><ArticleId IdType="pubmed">29740862</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Tauber C, Vercoullie J, et al. . Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7:e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratai EM, Alshikho MJ, Zurcher NR, et al. . Integrated imaging of [11C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy 1H-MRS in amyotrophic lateral sclerosis. Neuroimage Clin. 2018;20:357&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6092554</ArticleId><ArticleId IdType="pubmed">30112276</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D, Van Schoor E, De Vocht J, et al. . TSPO versus P2X7 as a target for neuroinflammation: an in vitro and in vivo study. J Nucl Med. 2020;61:604&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198372</ArticleId><ArticleId IdType="pubmed">31562223</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht DS, Normandin MD, Shcherbinin S, et al. . Pseudoreference regions for glial imaging with 11C-PBR28: investigation in 2 clinical cohorts. J Nucl Med. 2018;59:107&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5750517</ArticleId><ArticleId IdType="pubmed">28818984</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyoo CH, Ikawa M, Liow JS, et al. . Cerebellum can serve as a pseudo-reference region in Alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein. J Nucl Med. 2015;56:701&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4839390</ArticleId><ArticleId IdType="pubmed">25766898</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei A, Schramm G, Van Laere K, Nuyts J. Estimation of crystal timing properties and efficiencies for the improvement of (joint) maximum-likelihood reconstructions in TOF-PET. IEEE Trans Med Imaging. 2020;39:952&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7212322</ArticleId><ArticleId IdType="pubmed">31478844</ArticleId></ArticleIdList></Reference><Reference><Citation>Schramm G, Koole M, Willekens SMA, et al. . Regional accuracy of ZTE-based attenuation correction in static [18F]FDG and dynamic [18F]PE2I brain PET/MR. Front Phys. December 6, 2019 [Epub ahead of print].</Citation></Reference><Reference><Citation>Lavisse S, Garcia-Lorenzo D, Peyronneau MA, et al. . Optimized quantification of translocator protein radioligand 18F-DPA-714 uptake in the brain of genotyped healthy volunteers. J Nucl Med. 2015;56:1048&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">26025960</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo-Garcia D, Hansen AE, Forster S, et al. . An SPM8-based approach for attenuation correction combining segmentation and nonrigid template formation: application to simultaneous PET/MR brain imaging. J Nucl Med. 2014;55:1825&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4246705</ArticleId><ArticleId IdType="pubmed">25278515</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DR, Howell OW, Tang SP, et al. . Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab. 2010;30:1608&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2949260</ArticleId><ArticleId IdType="pubmed">20424634</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Flores S, Wang G, et al. . Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimers Dement (Amst). 2019;11:180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389727</ArticleId><ArticleId IdType="pubmed">30847382</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, et al. . The centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15 e11-14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisafulli SG, Brajkovic S, Cipolat Mis MS, Parente V, Corti S. Therapeutic strategies under development targeting inflammatory mechanisms in amyotrophic lateral sclerosis. Mol Neurobiol. 2018;55:2789&#x2013;2813.</Citation><ArticleIdList><ArticleId IdType="pubmed">28455693</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>